Major advancements in ovarian cancer maintenance therapy came with the advent of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) [10], which are currently approved in newly diagnosed and recurrent ovarian cancer maintenance. The gene discussed is PARP1; the disease is ovarian carcinoma.